Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units by unknown
RESEARCH ARTICLE Open Access
Clinical outcomes and molecular typing of
heterogenous vancomycin-intermediate
Staphylococcus aureus bacteremia in
patients in intensive care units
Han-Chung Hu1,2,3, Kuo-Chin Kao1,2,3†, Li-Chung Chiu1,3, Chih-Hao Chang1,3, Chen-Yiu Hung1,3, Li-Fu Li1,3,
Tsui-Ping Liu4, Lee-Chung Lin4, Ning-Hung Chen1,3, Chung-Chi Huang1,2,3, Cheng-Ta Yang1,2,3 and Jang-Jih Lu4,5*†
Abstract
Background: Staphylococcus aureus is one of most common pathogens in humans. Methicillin-resistant S. aureus
(MRSA) accounts for 64 % of S. aureus bacteremia isolated in intensive care units (ICUs), and heteroresistant
vancomycin-intermediates S. aureus (hVISA) is a phenotype of MRSA. However, studies focusing on the hVISA
impact on critically ill patients are scarce.
Methods: This was a retrospective study conducted in a tertiary medical center from January 2009 to December
2010. All adult patients in ICUs with MRSA bloodstream infection were eligible. A modified population analysis
profile and area under the curve method was applied to all isolates to confirm hVISA phenotype. Multilocus
sequence typing (MLST), staphylococcal cassette chromosome mec (SCCmec) and the accessory gene regulator
(agr) typing were performed individually. Clinical outcomes including in-hospital mortality, length of stay in
intensive care unit and hospital after MRSA bacteremia of the patients were also analyzed.
Results: A total of 48 patients were enrolled and 14 patients were confirmed to have the hVISA phenotype.
The prevalence of hVISA was 29.2 %. There was no difference in the age, sex, comorbidity, Charlson’s comorbidity
score and previous vancomycin therapy between the hVISA and VSSA groups. The hVISA group had a significantly
higher in-hospital mortality than the VSSA group (13/14 versus 22/34; p = 0.046). All of the 14 hVISA patients had
an MIC = 2 mg/L by E-test and this represented a significant association between high MIC and the development
of hVISA (p < 0.001). MLST analysis showed all the isolates in the hVISA group were ST239, while ST239 (14/34;
41.2 %) and ST5 (12/34; 35.3 %) were predominant in the VSSA group (p = 0.007). A comparison of the survivor
and non-survivor group showed that the hVISA phenotype (OR 11.8; 95 % CI 1.1–126.99; p = 0.042) and sequential
organ failure assessment (SOFA) score (OR 1.39; 95 % CI 1.07–1.81; p = 0.014) were independent factors significantly
associated with in-hospital mortality.
Conclusions: Patients in ICUs with MRSA bacteremia may have a higher in-hospital mortality if they have the hVISA
phenotype. SOFA score is also predictor of mortality.
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Background
Staphylococcus aureus is one of the most common path-
ogens in humans and may involve a variety of organs
such as eyes [1], cardiovascular system [2], osterarticular
system [3], skins and soft tissues, respiratory tract and
circulatory system [4]. Methicillin-resistant S. aureus
(MRSA) emerged several decades ago and is still a con-
cern worldwide, especially in critical ill patients because
of higher treatment costs and mortality rates [5]. Ac-
cording to a recent report, MRSA accounts for 64 % of
S. aureus bacteremia isolated in intensive care units
(ICUs) [6].
Vancomycin, a potent glycopeptide that has been used
for more than 50 years, is still regarded as the main agent
of treatment for MRSA. However, recent attention has fo-
cused on the emergence of isolates with decreased vanco-
mycin susceptibility. The first isolates with reduced
vancomycin susceptibility were detected in Japan in 1997
[7]. Since then heteroresistant vancomycin-intermediates
S. aureus (hVISA) has been considered a phenotype of
MRSA and has been reported throughout the world.
These hVISA isolates are resistant subpopulations that are
present in fully vancomycin susceptible S. aureus (VSSA)
at a rate of 1 per 105–106 organisms [8, 9]. They are con-
sidered as the stage preceding the development of VISA
and frequently occur in isolates with a minimum inhibi-
tory concentration (MIC) within the susceptible range
(≧2 mg/L by E-test) [10].
Previous study had reported the prevalence of hVISA
to range from 0 % to 50 % [10]. The causes of such wide
variance have to do with different geographic areas and
different screening and detection methods. Until now
there has been no standard method for early and easy
detection of isolates with hVISA; rather, the most ac-
cepted and reproducible method for detecting hVISA is
the modified population analysis profile (mPAP) and
comparing the area under the curve (AUC) with the
control strain Mu3 [11]. Because this method is labor-
intensive, it is not routinely used in clinical practice. In-
fections caused by hVISA have been associated with
vancomycin treatment failure, persistent bacteremia, and
prolonged hospital length of stay [12–14]. However, the
impact of hVISA bacteremia on mortality has yet to be
determined. A previous study reported that patients in-
fected with a certain genotype of hVISA were related to
lower mortality [13], yet another study found that mor-
tality rate was not affected at all [15]. Furthermore, prior
research enrolled all patients with MRSA bacteremia
regardless of the site of treatment and the severity of
illness, which may be, excluded the genotype of iso-
lates, causes of the different results between studies.
And while there was one report finding that in critic-
ally ill patients, MRSA bacteremia may cause more
acute renal failure and higher attributable mortality than
methicillin-susceptible S. aureus (MSSA) bacteremia [5],
studies focusing on hVISA impact on critically ill patients
are scarce.
The aim of this study was to survey the prevalence and
genotype of hVISA among patients in ICUs with MRSA
bacteremia. The risk factors for hVISA genotype such as
age, primary infection site, comorbidity or history of gly-
copeptide exposure were also analyzed. A secondary aim
was to compared the clinical features and outcomes be-
tween patients with hVISA and vancomycin-susceptible S.
aureus (VSSA) bacteremia. Finally, we investigated the in-
dependent predictors for in-hospital mortality between
survivor and non-survivor.
Methods
Study design and patients
This was a retrospective study conducted in a tertiary
medical center with a 3700-bed general ward and a
278-bed adult ICU in northern Taiwan. From January
2009 to December 2010, patients with MRSA blood-
stream infection (BSI) and treated in ICUs were eligible
for the study. The definition of MRSA BSI was patients
with MRSA in blood cultures and met the Centers for
Disease Control and Prevention (CDC) criteria for blood-
stream infection. [16] Adult patients (aged ≧ 18 years) and
single pathogen in blood culture were included. If there
was recurrent MRSA bacteremia or persistent bacteremia
(> 7 days), only the isolate of MRSA and the data of the
first episode was analyzed. This study was approved by the
Chang Gung Medical Foundation Institutional Review
Board (103-4279B).
Clinical data
Data collection from patient medical records included:
age, gender, admission date, presence of co-morbidity,
Charlson comorbidity score, sequential organ failure as-
sessment (SOFA) score, primary site of infection, history
of glycopeptide use in the previous 1 month, receipt of
chemotherapy or other immunosuppressive therapy in
the previous 1 month, and concomitant antibiotics used
in this episode. The primary site of infection was deter-
mined by assessment of other MRSA-positive cultures at
the time of the MRSA blood culture. Other immunosup-
pressive therapy included ≥10 mg/day prednisone or
equivalent for more than 2 weeks or any dose of another
immunosuppressant. Hospital-acquired infection was
defined as the positive blood cultures obtained more
than 48 h after admission. Hemodyalysis meaned pa-
tients ever receiving renal replacemen therapy, either
regularly or acute episode, during the bacteremia treat-
ment. Antibiotic treatment was considered adequate if
the used drug was susceptible to the isolated MRSA.
During the treatment course of MRSA bactereremia, if
pateitns treated with norepinephrine treatment more
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than 5 μg per minute or an equivalent dose of other
vasopressor for 4 h or more was defined as shock epi-
sode. The status at discharge (alive or deceased) was
recorded. We also calculated the admission days to first
culture, that meaned the numbers of days from admis-
sion to performing blood culture.
Outcomes assessment included in-hospital mortality,
the length of ICU stay and hospital stay after MRSA
bacteremia. In-hospital mortality means patients’ status
at discharge were deceased. Length of ICU stay after
MRSA bacteremia was the numbers of days from the
first positive blood culture to be transferred to ward or
death. Length of hospital stay after MRSA bacteremia
was the numbers of days from the first positive blood
culture to discharge or death. For the purpose of ana-
lysis, patients were stratified into survivor and non-
survivor group according to the status of discharge (alive
or deceased). Mortality was considered to be attributable
to MRSA bacteremia if blood cultures were positive for
MRSA at the time of death, or if death occurred before
the resolution of the signs and symptoms of MRSA in-
fection or if death occurred within 14 days after the on-
set MRSA bacteremia without another explanation [17].
Microbiological and molecular methods
The MIC of vancomycin was determined by broth micro-
dilution according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines [18] and the suscep-
tibility breakpoint was ≦ 2 mg/L. The E-test (bioMérieux)
was also performed according to the manufacturer’s in-
structions for all isolates. All isolates were further analyzed
by the mPAP-AUC method as previously described [11],
with hVISA being confirmed if the ratio of the AUC of
MRSA isolates to the reference strain Mu3 (ATCC
700,698) was ≧ 0.9. The staphylococcal cassette chromo-
some mec (SCCmec) and the accessory gene regulator
(agr) typing were analyzed with multiplex PCR as de-
scribed elsewhere [19, 20]. The agr function was deter-
mined by δ-hemolysin activity, and agr dysfunction may
result in a reduction or absence of of δ-hemolysin produc-
tion. Detection of δ-hemolysin production by means of
previously reported [21], briefly, the production of
δ-hemolysin was measured by crossstreaking perpendicu-
larly to S. aureus RN4220, which produces β-hemolysin
and enhance blood lysis by δ-hemolysin. δ-Hemolysin
produced by a test isolate causes an enhanced hemolysis
in the area where the hemolysis zone of the test strain
overlaps with that of RN4220. Therefore, the absence
of synergistic hemolysis (δ-hemolysis negative) at the
intersection of the streaks of RN4220 represents agr
dysfunction. Multilocus sequence typing (MLST) was
also performed for all isolates, as described by Enright
et al. [22].
Statistical analysis
Continuous variables were compared using Student’s
t-test or the Mann–Whitney U-test and are presented as
mean ± SD. Categorical variables were analyzed using
the χ2 test or Fisher’s exact test as appropriate. Risk fac-
tors for in-hospital mortality were analyzed by using uni-
variable analysis. The variables significantly associated
with the outcome on analysis (P ≤ 0.2) were included in
the multivariable analysis by applying a multiple logistic
regression based on backward elimination of data. The
Hosmer-Lemeshow goodness-of-fit test was used for
calibration when evaluating the number of observed and
predicted deaths in risk groups for the death probabil-
ities. All statistical analyses were performed using SPSS,
version 15.0 (SPSS, Inc, Chicago, IL, USA). All statistical
tests were two-tailed and a p value of less than 0.05 was
considered to be statistically significant.
Results
During the study period, there were a total of 117 pa-
tients with MRSA bacteremia in our hospital and 48 pa-
tients fulfilled this study’s criteria. In the 69 excluded
patients, 2 were VISA and others were treated at ward.
Of the 48 isolates, 14 (29.2 %) harbored the hVISA
phenotype. The baseline demographics and clinical out-
comes were compared between the two groups and are
shown in Table 1. There was no difference in the age,
sex, comorbidity, Charlson comorbidity score and previ-
ous vancomycin therapy. The SOFA score represented
the severity of illness when MRSA bacteremia developed
and there was also no differentce between the hVISA
and VSSA groups. The primary site of infection was dif-
ferent among the two groups, and we were unable to lo-
cated the origin of infection for 7 patients (50 %) in the
hVISA group while pneumonia was predominant (18/34;
52.9 %) in the VSSA group. The clinical outcomes be-
tween these two groups are also shown in Table 1. There
was a trend of the hVISA group having a longer hospital
stay in the days before the MRSA episode, although
there was no statistical significance (44.5 ± 48.3 versus
27.0 ± 20.5; p = 0.08). Attributable mortality from MRSA
bacteremia was 42.9 % (6/14) in the hVISA group, and
this was not different from the VSSA group (14/34,
41.2 %) (p = 0.915). The number of days in the ICU
and for hospital stay after this episode also showed no
statistical difference between these two groups. How-
ever, the hVISA group had a significantly higher in-
hospital mortality than the VSSA group (13/14 versus
22/34; p = 0.046).
Table 2 shows the distribution of vancomycin MICs
and genotype among our hVISA and VSSA isolates. All
of the 14 hVISA patients had an MIC = 2 mg/L by E-test
and this represented a significant association between a
high MIC and the development of hVISA (p < 0.001).
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Genotype analysis using MLST indicated a significant
difference between the two groups (p = 0.007): all iso-
lates in the hVISA group werewas ST239 (sequence type
239) in hVISA group, while ST239 (14/34; 41.2 %) and
ST5 (12/34; 35.3 %) were predominant in the VSSA
group. In the SCCmec type analysis, most isolates were
associated with type II and III (100 % in the hVISA and
79.4 % in the VSSA group), which is compatible with the
hospital-acquired nature of the infection (all were
hospital-acquired infection). In the hVISA group, 10
patients (71.4 %) had an agr dysfunction, which was
significantly higher than that in the VSSA group
(8.8 %; p < 0.001).
Overall in-hospital mortality was 72.9 % (35/48) in our
study. Table 3 presents the univariate analysis of mul-
tiple factors for mortality, which indicates that hVISA
phenotype (Odds ratio [OR] 7.09; 95 % confidence inter-
val [CI] 0.82-61.01; p = 0.046), SOFA score (OR 1.33;
95 % CI 1.05–1.68; p = 0.009) and received hemodialysis
(OR 6.53; 95 % CI 1.26–33.9; p = 0.016) were shown to
be associated with in-hospital mortality. Comorbidity of
cerebrovascular accident (CVA) seemed to have a pro-
tective effect on the survival of these patients for un-
known reasons. Other factors such as age, primary site
of infection, shock episode, agr dysfunction and MIC
did not appear to be significantly different between
survivors and non-survivors. In a multivariate logistic
regression analysis, SOFA score (OR 1.39; 95 % CI
1.07–1.81; p = 0.014) and hVISA (OR 11.8; 95 % CI
1.1–126.99; p = 0.042) were found to be independent
predictors of in-hospital mortality (Table 4).
Table 1 Demographic and clinical outcomes for intensive care
patients with hVISA and VSSA bacteraemiaa
hVISA (n = 14) VSSA (n = 34) p value
Patient demographics
Median age (years) 71.4 ± 16.9 69.7 ± 12.3 0.76
Male sex 9 (64.3) 18 (52.9) 0.47
Comorbidity
Chronic renal disease 5 (35.7) 13 (38.2) 0.87
Solid organ malignancy 3 (21.4) 5 (14.7) 0.57
Hematological malignancy 1 (7.1) 1 (2.9) 0.508
Diabetes mellitus 4 (28.6) 14 (41.2) 0.412
Liver cirrhosis 4 (28.6) 5 (14.7) 0.263
Heart disease 1 (7.1) 8 (23.5) 0.186
Chronic pulmonary disease 1 (7.1) 1 (2.9) 0.508
Cerebrovascular accident 2 (14.3) 10 (29.4) 0.271
Primary site of infection 0.045
Catheter-related infection 1 (7.1) 6 (17.6)
Pneumonia 6 (42.9) 18 (52.9)
Surgical wound infection 0 3 (8.8)
Other 0 3 (8.8)
Unknown 7 (50) 4 (11.8)
CRP 147.3 ± 11.3 132.6 ± 75.6 0.62
Albumin 2.5 ± 0.5 2.5 ± 0.6 0.82
Charlson comorbidity score 2.7 ± 1.6 3.1 ± 2.1 0.307
SOFA score 8 ± 3.2 8.4 ± 4.1 0.774
Prior vancomycin therapy 5 (35.7) 10 (29.4) 0.669
Adequate antibiotics treatment 3 12 0.279
Hemodialysis 7 14 0.403
Shock after infection 4 13 0.386
Outcomes
In-hospital mortality 13 (92.9) 22 (64.7) 0.046
Attributable mortality by
MRSA bacteremia
6 (42.9) 14 (41.2) 0.915
Length of stay in hospital
after MRSA bacteremia (days)
32.6 ± 34.4 33.4 ± 49.3 0.96
Length of stay in ICU
after MRSA bacteremia (days)
27.7 ± 31.5 21.2 ± 45.9 0.629
Admission days to first culture 44.5 ± 48.3 27.0 ± 20.5 0.083
aAll values presented as number (%) or mean value ± SD unless otherwise
indicated
CRP C-reactive protein
Table 2 Microbiological and genotypic characteristics of hVISA
and VSSA bacteriaemia in ICU
Isolation no. (%)
hVISA (n = 14) VSSA (n = 34) p
Vancomycin MIC
(E test) < 0.001
1 mg/L 0 6
1.5 mg/L 0 18
2 mg/L 14 10
MLST 0.007
ST-239 14 (100) 14 (41.2)
ST-5 0 12 (35.3)
ST-59 0 5 (14.7)
ST-45 0 2 (5.9)
ST-1 0 1 (2.9)
SCCmec type 0.095
II 5 (35.7) 17 (50)
III 9 (64.3) 10 (29.4)
IV 0 5 (14.7)
V 0 2 (5.95)
agr subgroup 0.4
1 11 (78.6) 20 (58.8)
2 3 (21.4) 13 (38.2)
3 0 1 (2.9)
agr dysfunction 10 (71.4) 3 (8.8) <0.001
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Discussion
This retrospective study analyzed 48 patients with
MRSA bacteremia treated in ICUs, which is a group of
patients seldom the focus of previous reports, and re-
vealed the prevalence of the hVISA phenotype in our
hospital was 29.2 %. The overall in-hospital mortality
was 72.9 % (35/48) in this study, but the in-hospital
mortality of the hVISA group rose to 92.9 % (13/14).
Previous studies have noted that the frequency of
hVISA phenotype is associated with high vancomycin
MIC, which means a higher hVISA rate when the MICs
are higher [10, 13, 23]. All of the MICs of the hVISA iso-
lates in our data were 2 mg/L by E-test, which is consist-
ent with these reports. Prior research pointed out that
the hVISA phenotype may cause glycopeptides treatment
failure (defined as prolonged symptoms or persistent
bacteremia) with a variable range [12, 24], and a meta-
analysis study also revealed that hVISA infection had a
2.3 times greater failure rate compared to that of VSSA
infection (95 % CI, 1.53 to 3.67) [25]. In our hospital, we
do not routinely follow blood culture, and only do so
when the patients have persistent fever or prolonged
symptoms after the appropriate glycopeptide treatment;
however, we did not observe the similar adverse effect
caused by hVISA in our study.
Although the impact of the hVISA genotype on clinical
outcomes has been extensively explored in previous
studies, their results have been conflicting. For example,
whereas Van Hal et al. recently found that hVISA in the
ST239 MRSA strain was an independent predictor of
survival [13], Park and colleagues reported that the most
common genotype of hVISA in their hospital was ST5
and there was no obvious impact on patients’ outcomes
[15]. In our study, all-cause mortality was significantly
high in the hVISA isolates which were all of the ST239
strain. The inconsistent results between studies may be
due to the different pathogen factors related to geo-
graphic variation, different case selection and different
definitions of outcomes. Furthermore, the uncertainty of
the conclusions also suggests that other possible causes,
such as genetic factors, in addition to sequence type
(ST) may affect an organism’s virulence factors and a pa-
tient’s clinical outcomes.
SCCmec type has been used to distinguish community-
associated MRSA (CA-MRSA) from healthcare-associated
MRSA (HA-MRSA) and type II and III are the more likely
type in HA- MRSA strains [26] In previous studies,
SCCmec II was the predominant genotype and associated
with reducing vancomycin susceptibility and increasing
the presence of hVISA [27, 28], but there no significant ef-
fect on outcomes such as vancomycin failure or persistent
bacteremia were found in either study. Similarly, the
Table 3 Clinical features of patients with MRSA bacteraemia







Median age (years) 76.5 ± 11.5 67.8 ± 18.2 0.114
Male sex 7 20 0.838
hVISA 1 13 0.046
Charlson comorbidity score 2.4 ± 1.4 3.2 ± 2.1 0.207
SOFA score 5.9 ± 3.0 9.1 ± 3.8 0.009
Hemodialysis 2 19 0.016
Comorbidity
Chronic renal disease 3 (23.1) 15 (42.9) 0.208
Solid organ malignancy 2 6 0.885
Hematological malignancy 0 2 0.379
Diabetes mellitus 7 11 0.154
Liver cirrhosis 1 8 0.232
Heart disease 3 6 0.640
Chronic pulmonary disease 0 2 0.379
Cerebrovascular accident 7 5 0.005
Primary site of infection 0.72
Catheter-related infection 3 4
Pneumonia 6 18
Surgical wound infection 1 2
Other 0 3
Unknown 3 8
CRP 139.5 ± 84.7 135.6 ± 88.5 0.897
Albumin 2.6 ± 0.8 2.4 ± 0.5 0.425
Prior vancomycin therapy 4 11 0.627
Adequate antibiotics treatment 3 12 0.48
Shock after infection 2 15 0.077
agr dysfunction 1 (7.7) 12 (34.3) 0.065
Vancomycin MIC (Etest) 0.111
1 mg/L 1 5
1.5 mg/L 8 10
2 mg/L 4 20
aAll values presented as number (%) or mean value ± SD unless otherwise
indicated
CRP C-reactive protein
Table 4 Logistic regression analysis of clinical variables








SOFA score 0.329 0.134 1.39 (1.07–1.81) 0.014
hVISA 2.468 1.213 11.8 (1.1–126.99) 0.042
Constant 1.745 2.205 5.727 0.429
C.I.: confidence interval; In multivariable logistic regression, the Hosmer–
Lemeshow test results (χ2 = 12.728, degrees of freedom = 8, P = 0.122)
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SCCmec type did not produce similar adverse outcomes
in our study, but hVISA isolates were discovered to more
likely harbour SCCmec III (9/14; 64.3 %). The different
genotype of SCCmec in studies also indicates the variation
of microbiological characteristics in different areas, as was
mentioned above.
The agr gene controls staphylococcal virulence and
several metabolic pathways, with a number of studies
showing that agr dysfunction may be related to persist-
ent bacteremia, attenuated vancomycin bactericidal ac-
tivity, vancomycin heteroresistance and the development
of vancomycin-intermediate S. aureus (VISA) phenotype
[29–31]. Schweizer et al. demonstrated that agr dysfunc-
tion was significantly associated with increasing mortal-
ity in severely ill patients [32]. In our study, the majority
of hVISA isolates (10/14; 71.4 %) were agr dysfunction,
while only being 8.8 % in the non-hVISA group. We also
found that there was a trend of higher in-hospital mor-
tality in the defective agr gene group (p = 0.065), al-
though the figures did not reach statistical significance.
The small sample size may have impacted on the results.
As mention earlier that S.aureus bacteremia is, par-
ticularly in ICU, a leading cause of death in nosocomial
infection with mortality rate that is as high as 50 %. Blot
et al. compared outcomes in critically ill patients with
MSSA and MRSA bacteremia and demonstrated that
MRSA bacteremia had a higher attributable mortality.
Acute renal failure, age and length of mechanical venti-
lation were factors associated with mortality in this
group of patients [5]. Van Hal et al. analyzed all of the
severity levels of patients with MRSA bacteremia and
concluded that age, severity of illness, and transit to ICU
were independent predictors of 30-day mortality [13],
but hVISA may reduce mortality in a ST239 genotype
MRSA infection. However, since there has been scant
published evidence on the effect of hVISA on the mor-
tality of critically ill patients, we focused on this group
of patients and analyzed the possible predictive factors
of all causes mortality. The results showed that the over-
all mortality in our study was relative high, choosing the
serious population only and selecting in-hospital mortal-
ity as aim may correlate to the poor ouctome. In multi-
variable analysis, the hVISA phenotype and severity of
illness (SOFA score) were predictors of in-hospital mor-
tality in ICU patients with MRSA bacteremia. This result
indicated that the hVISA phenotype may bring a adverse
outcomes in critically ill patients.
Naturally, there are limitations in our study. First, this
was a retrospective study and performed in a single cen-
ter, which means that data collection was restricted and
incomplete for some factors, and our data only reflected
the phenotype and genotype of MRSA in our institution.
Second, the sample size was small because we concen-
trated on critically ill patients; different conclusions may
have been reached in a multivariate analysis if we ex-
panded the number of enrolled cases. We also lack some
data such as the storage period of isolates before they
were tested and the time to appropriate therapy, these
variables may also impact the results. Despite these limi-
tations, we believe this study can provide us with a
better understanding of the impact of MRSA bacteremia
in severely ill patients.
Conclusions
From this study we found that the prevalence of hVISA
was 29.2 % in our critically ill patients. This phenotype
was associated with high vancomycin MIC within the
susceptibility range and also the highly defective agr
gene. Factors such as hVISA phenotype and SOFA score
were predictors of in-hospital mortality. Further pro-
spective, large scale studies are needed to further valid-
ate these findings.
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